Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 27 Parkinson Disease 4, Autosomal Dominant Lewy Body 24 Neoplasms 14 Melanoma 9 Endometrial Neoplasms 8 Carcinoma, Renal Cell 7 Carcinoma, Non-Small-Cell Lung 7 Thyroid Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Cholangiocarcinoma 6 Stomach Neoplasms 4 Recurrence 4 Carcinoma 4 Biliary Tract Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Lymphoma 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Paraganglioma, Extra-Adrenal 2 Osteosarcoma 2 Neuroendocrine Tumors 2 Lung Neoplasms 2 Liver Neoplasms 2 Glioma 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, Hurthle cell 1

Interventions

Doxorubicin 14 Radiotherapy 10 Ifosfamide 10 Trabectedin 7 pazopanib 4 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 temsirolimus 2 romidepsin 2 ribociclib 2 pegfilgrastim 2 eribulin 2 cixutumumab 2 brigimadlin 2 belinostat 2 Vincristine 2 Sunitinib 2 Radiotherapy, Conformal 2 Gemcitabine 2 Epirubicin 2 Dexamethasone 2 Dactinomycin 2 Carboplatin 2 soblidotin 1 sitravatinib 1 siremadlin 1 selinexor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Liposarcoma × lenvatinib × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡